CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
A Phase 1/2 Study of CB-103 (Oral Pan-NOTCH Inhibitor) With Abemaciclib or Lenvatinib in Combination in Patients With NOTCH Activated Adenoid Cystic Carcinoma (CALCulus)
Sponsor: Adenoid Cystic Carcinoma Research Foundation
A PHASE1/PHASE2 clinical study on Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, this trial is actively recruiting participants. The trial is conducted by Adenoid Cystic Carcinoma Research Foundation and has accumulated 8 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Jul 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
Status: Active Not Recruiting → Recruiting
-
Nov 2024 — Jul 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jul 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Apr 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Adenoid Cystic Carcinoma Research Foundation
- Cellestia Biotech AG
- Glenn J. Hanna
For direct contact, visit the study record on ClinicalTrials.gov .